Fig. 1.

Achievement over time of ACR improvement endpoints and MDA. ACR20/50/70 ≥ 20%/≥ 50%/≥ 70% improvement in American College of Rheumatology criteria for symptoms of rheumatoid arthritis, CI confidence interval, MDA minimal disease activity, NRI-C, nonresponder imputation incorporating multiple imputations to handle missing data due to COVID-19, NRI-MI nonresponder imputation incorporating multiple imputations to handle missing data due to COVID-19 and geopolitical conflict, and all other missing data treated as nonresponders, including missing data and patients who received rescue therapy, PBO placebo, RZB risankizumab